Related Experiment Video
Updated: May 9, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Tofacitinib in kidney transplantation.
David Wojciechowski1, Flavio Vincenti
1University of California, Kidney Transplant Service, San Francisco, CA 94143-0780, USA.
Expert Opinion on Investigational Drugs
|July 12, 2013
Summary
Tofacitinib, a Janus kinase (JAK) 3 inhibitor, shows promise as a kidney transplant immunosuppressant, offering similar efficacy to cyclosporine with fewer cardiometabolic risks. However, increased infection rates require further study for optimal use.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Kidney transplantation necessitates effective immunosuppression to prevent rejection.
- Current calcineurin inhibitor protocols carry risks of nephrotoxicity and adverse cardiometabolic effects.
- Janus kinases (JAKs) are key in cytokine signaling pathways, with JAK3 inhibition offering immunosuppressive potential.
Purpose of the Study:
- To review the mechanism of action of tofacitinib, a JAK3 inhibitor.
- To examine clinical trial data for tofacitinib in kidney transplantation.
- To evaluate tofacitinib as an alternative to calcineurin inhibitors in renal transplant recipients.
Main Methods:
- Review of existing literature on tofacitinib's pharmacology and clinical trial outcomes.
- Analysis of data from nonhuman primate renal transplantation models.
- Evaluation of human renal transplant clinical trial results comparing tofacitinib to cyclosporine.
Main Results:
- Tofacitinib demonstrated immunosuppressive effects and efficacy in autoimmune conditions.
- Nonhuman primate studies showed prolonged graft survival with tofacitinib.
- Human trials indicated tofacitinib is noninferior to cyclosporine for rejection rates and graft survival, with a lower incidence of new-onset diabetes after transplant.
- A trend towards increased infections, including CMV and BK virus nephritis, was observed.
Conclusions:
- Tofacitinib presents a potential alternative to calcineurin inhibitors in kidney transplantation.
- Further research is needed to establish the optimal therapeutic window for tofacitinib.
- Risk-benefit analysis regarding infection rates requires careful consideration.
Related Concept Videos
01:28Kidney Transplant I: Introduction
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
01:16Kidney Transplant III: Nursing Management
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
01:26Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24Tissue Transplantation
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...